These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Loss of Hepatic Mitochondrial Long-Chain Fatty Acid Oxidation Confers Resistance to Diet-Induced Obesity and Glucose Intolerance. Lee J; Choi J; Selen Alpergin ES; Zhao L; Hartung T; Scafidi S; Riddle RC; Wolfgang MJ Cell Rep; 2017 Jul; 20(3):655-667. PubMed ID: 28723568 [TBL] [Abstract][Full Text] [Related]
8. Loss of long-chain acyl-CoA synthetase isoform 1 impairs cardiac autophagy and mitochondrial structure through mechanistic target of rapamycin complex 1 activation. Grevengoed TJ; Cooper DE; Young PA; Ellis JM; Coleman RA FASEB J; 2015 Nov; 29(11):4641-53. PubMed ID: 26220174 [TBL] [Abstract][Full Text] [Related]
9. SIRT2 Acts as a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy. Tang X; Chen XF; Wang NY; Wang XM; Liang ST; Zheng W; Lu YB; Zhao X; Hao DL; Zhang ZQ; Zou MH; Liu DP; Chen HZ Circulation; 2017 Nov; 136(21):2051-2067. PubMed ID: 28947430 [TBL] [Abstract][Full Text] [Related]
10. Loss of Muscle Carnitine Palmitoyltransferase 2 Prevents Diet-Induced Obesity and Insulin Resistance despite Long-Chain Acylcarnitine Accumulation. Pereyra AS; Rajan A; Ferreira CR; Ellis JM Cell Rep; 2020 Nov; 33(6):108374. PubMed ID: 33176143 [TBL] [Abstract][Full Text] [Related]
11. Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy. Zhang L; Jaswal JS; Ussher JR; Sankaralingam S; Wagg C; Zaugg M; Lopaschuk GD Circ Heart Fail; 2013 Sep; 6(5):1039-48. PubMed ID: 23861485 [TBL] [Abstract][Full Text] [Related]
12. Glucose transporter 4-deficient hearts develop maladaptive hypertrophy in response to physiological or pathological stresses. Wende AR; Kim J; Holland WL; Wayment BE; O'Neill BT; Tuinei J; Brahma MK; Pepin ME; McCrory MA; Luptak I; Halade GV; Litwin SE; Abel ED Am J Physiol Heart Circ Physiol; 2017 Dec; 313(6):H1098-H1108. PubMed ID: 28822962 [TBL] [Abstract][Full Text] [Related]
13. HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes. Ooi JY; Tuano NK; Rafehi H; Gao XM; Ziemann M; Du XJ; El-Osta A Epigenetics; 2015; 10(5):418-30. PubMed ID: 25941940 [TBL] [Abstract][Full Text] [Related]
14. Folliculin (Flcn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation. Hasumi Y; Baba M; Hasumi H; Huang Y; Lang M; Reindorf R; Oh HB; Sciarretta S; Nagashima K; Haines DC; Schneider MD; Adelstein RS; Schmidt LS; Sadoshima J; Marston Linehan W Hum Mol Genet; 2014 Nov; 23(21):5706-19. PubMed ID: 24908670 [TBL] [Abstract][Full Text] [Related]
15. mTORC1 activation is not sufficient to suppress hepatic PPARα signaling or ketogenesis. Selen ES; Wolfgang MJ J Biol Chem; 2021 Jul; 297(1):100884. PubMed ID: 34146544 [TBL] [Abstract][Full Text] [Related]
16. Upregulation of C/EBPβ and TSC2 by an HDAC inhibitor CG200745 protects heart from DOCA-induced hypertrophy. Lee E; Lee HA; Kim M; Do GY; Cho HM; Kim GJ; Jung H; Song JH; Cho JM; Kim I Clin Exp Pharmacol Physiol; 2019 Mar; 46(3):226-236. PubMed ID: 30099761 [TBL] [Abstract][Full Text] [Related]
17. Loss of Adipose Fatty Acid Oxidation Does Not Potentiate Obesity at Thermoneutrality. Lee J; Choi J; Aja S; Scafidi S; Wolfgang MJ Cell Rep; 2016 Feb; 14(6):1308-1316. PubMed ID: 26854223 [TBL] [Abstract][Full Text] [Related]